For years, cannabis companies operating legally under state law have faced a tax burden with no real parallel in American business: a federal rule that denied them the standard deductions available to virtually every other industry, from dry cleaners to pharmaceutical manufacturers. That changes - at least partially - following the Department of Justice's April 23 final order moving certain medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act, a shift that effectively strips Section 280E of its teeth for a significant slice of the cannabis industry. The Treasury Department, responding the same day, announced that it and the IRS will issue formal guidance on how to implement that relief.
What Section 280E Actually Did - and Why It Stung
Section 280E is a provision most industries never have to think about. Its language is blunt: no deductions, no credits, for any business trafficking in Schedule I or Schedule II controlled substances. It was written in the early 1980s, reportedly in response to a drug dealer who had successfully claimed business expense deductions, and it was never meant to apply to a multi-billion-dollar licensed industry operating in plain sight under state regulatory frameworks. Yet that is precisely what happened as state after state legalized medical and recreational marijuana while federal scheduling remained frozen.
The practical effect was severe. A cannabis dispensary couldn't deduct rent, payroll, utilities, or marketing costs the way any other retailer could. Only the cost of goods sold - the direct costs of producing the product itself - remained deductible under a separate provision. This pushed effective federal tax rates on cannabis businesses dramatically higher than those faced by comparable businesses in unrelated industries, in some cases consuming the bulk of operating profit. The thing is, these weren't underground operations; many were publicly traded, heavily regulated, and paying substantial state and local taxes on top of everything else.
What the DOJ Order Actually Covers - and What It Doesn't
Here's the catch with the April 23 rescheduling order: it is targeted, not sweeping. The order applies to marijuana contained in FDA-approved drug products, marijuana subject to a state medical marijuana license, certain marijuana extracts, and certain naturally derived delta-9 tetrahydrocannabinols. That covers a meaningful portion of the commercial market - but not all of it.
Left in Schedule I: unlicensed marijuana crops, bulk marijuana, and marijuana or extract not yet incorporated into an FDA-approved product. For businesses with mixed operations - say, a vertically integrated company that cultivates, processes, and dispenses - the line between deductible and non-deductible activities won't always be clean. Treasury and the IRS have acknowledged this directly, stating they expect forthcoming guidance to address expense apportionment where some activities continue to involve Schedule I or II substances. That guidance can't come soon enough.
On timing, Treasury has signaled a transition rule: Section 280E relief will apply to the first full taxable year that includes April 22, the order's effective date. For most calendar-year filers, that means the 2025 tax year - which is welcome clarity, even if the underlying apportionment math will remain complex for companies straddling both schedules.
Retroactive Relief and the Road Ahead
One of the more consequential passages in the DOJ's order is its encouragement to Treasury to consider retroactive relief - specifically, relief from Section 280E liability for taxable years in which a state licensee operated under a valid state medical marijuana license. Treasury's press release does not yet commit to retroactivity, but it flags the issue as something forthcoming guidance will address. For cannabis companies that have been paying elevated effective tax rates for years, even partial retroactive relief could translate into meaningful refund opportunities and amended-return filings worth examining carefully with tax counsel.
The DOJ has also indicated that further hearings in June will address the broader status of marijuana scheduling, leaving open the possibility that the categories of rescheduled products could expand. The industry, in other words, is watching two processes at once: Treasury guidance that will define how existing relief works, and a continued federal regulatory process that may widen the aperture further.
For cannabis businesses right now, the practical priorities are straightforward even if the execution isn't. Evaluate which products and revenue streams fall under the new Schedule III designation and which remain in Schedule I. Review expense allocation documentation - the IRS will want to see a defensible methodology, and sloppy recordkeeping now will cost significantly more later. Assess whether existing tax accounting methods for inventory, depreciation, and cost capitalization still make sense as the 280E constraint lifts from part of the business. And for any company currently under IRS examination or in litigation over 280E, the rescheduling order changes the calculus on settlement and litigation posture in ways that merit immediate discussion with legal and tax advisers.
None of this resolves overnight. But after more than a decade of watching the rest of American business operate under one tax code while cannabis companies operated under another, the structural correction has finally, if partially, arrived.
